Amrutanjan to bolt CMO services on to fine chemicals unit
Amrutanjan Health Care plans to add contract manufacturing and custom synthesis to services offered by loss making fine chemicals business, according to various reports.
The Chennai, India headquartered healthcare firm told the country’s Business Standard that the move is designed to revive the fortunes of its unit, Pharmaessence Chemistry Services, which has posted a losses of INR28m ($580,912) and INR34m for the two previous financial years.
Sambhu Prasad, managing director, AHCL told the paper: "This is part our plans to turnaround the subsidiary in the next two to three years. We are looking at tie-ups to develop and manufacture high-value small-volume drugs including for clinical supply from our GMP compliant lab.”
The firm did not respond to Outsourcing-pharma.com’s request for additional information ahead of publication.
